NCT02998970View on ClinicalTrials.gov

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

PHASE4UnknownINTERVENTIONAL

Enrollment

97

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

DiabetesCardiovascular Disease

Interventions

DRUG

Empagliflozin

single oral tablet once daily.

DRUG

Placebo

single oral tablet once daily.

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Unity Health Toronto

OTHER